Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.
Actively Recruiting
Major depressive disorder MDD is a mood disorder causing ongoing sadness and loss of interest, with emotional and physical symptoms such as irritability, difficulty focusing, tiredness, and changes in eating habits. Researchers are studying oral Icalcaprant, an investigational drug, to assess its effects on disease activity and side effects in adults currently experiencing a major depressive episode. Participants are randomly assigned to one of three groups two different doses of Icalcaprant or a placebo. They will take oral capsules once daily for 6 weeks, followed by a 30-day safety follow-up period. The study is conducted at about 35 sites across North America and involves approximately 195 adults. During the study, participants will attend regular visits at a hospital or clinic where medical assessments, blood tests, side effect checks, and questionnaires will be completed. Researchers will measure changes in depression severity using scales like the Montgomery-sberg Depression Rating Scale MADRS over about 6 weeks, and adverse events will be monitored for up to 10 weeks total.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.
Actively Recruiting
Researchers are studying the effects of lumateperone in children and teenagers aged 10 to 17 who have major depressive episodes linked to bipolar I or bipolar II disorder. This is a multicenter, randomized, double-blind study comparing lumateperone to a placebo to understand its potential impact on bipolar depression in pediatric patients. The diagnosis is confirmed using a structured psychiatric interview following DSM-5 criteria. Participants will take either lumateperone or a matching placebo once daily during a 6-week double-blind treatment period. Dosage varies by age, with patients aged 13 to 17 receiving 42 mg and those aged 10 to 12 receiving 21 mg. The study is divided into three phases an initial screening period of up to 2 weeks, the 6-week treatment phase, and a 1-week safety follow-up after the last dose. During the study, participants will undergo assessments including the Childrens Depression Rating Scale-Revised CDRS-R to measure depression severity. Safety will be monitored throughout the trial with a follow-up visit about one week after treatment ends. The study aims to evaluate changes in depressive symptoms over the 6-week treatment, with all visits and assessments scheduled accordingly.
Actively Recruiting
Researchers are evaluating lumateperone in a study involving children and teenagers aged 5 to 17 years who have irritability linked to Autism Spectrum Disorder ASD. This is a randomized, double-blind, placebo-controlled trial aimed at assessing the safety and effectiveness of lumateperone in this pediatric population. Diagnosis is confirmed using DSM-5-TR criteria and the K-SADS-PL assessment tool. Participants will be randomly assigned to one of three groups to receive either a high dose of lumateperone 42 mg, a low dose of lumateperone 21 mg, or a placebo. The treatment is taken orally once daily during a 6-week double-blind period. The study includes an initial screening phase lasting up to 14 days, and a safety follow-up visit occurs about one week after the last dose. During the study, participants will attend visits for screening, treatment, and safety follow-up. Researchers will evaluate irritability using the Aberrant Behavior Checklist - Irritability subscale at 6 weeks, along with the Clinical Global Impression-Severity scale. Safety monitoring will be conducted throughout, and total participation spans screening, 6 weeks of treatment, and a 1-week follow-up period.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
Actively Recruiting
Researchers are evaluating the safety and tolerability of lumateperone in children and adolescents diagnosed with schizophrenia, bipolar disorder, or autism spectrum disorder. This open-label, multicenter study lasts 26 weeks and aims to better understand how this medication affects pediatric patients with these conditions. The study includes patients who are either new to treatment or rolling over from previous related studies. Participants will receive lumateperone once daily in capsule or orally disintegrating tablet form, with doses ranging from 5 mg to 42 mg based on their age and condition. The trial begins with a screening period up to 2 weeks to confirm eligibility, followed by a 26-week treatment phase where all participants receive open-label lumateperone. After treatment, there is a 2-week safety follow-up visit approximately 2 weeks after the last dose. Throughout the study, participants will attend clinic visits for monitoring and assessments. Researchers will collect safety data, including tracking common adverse events up to six months. Patients must be outpatients expected to remain so during the study. Safety follow-up helps ensure ongoing monitoring after treatment ends, with the entire participation lasting about 28 weeks including screening and follow-up.
Actively Recruiting
Researchers are evaluating lumateperone as an additional treatment for adults aged 18 to 65 years with major depressive disorder MDD who have not responded adequately to current antidepressant treatments. This phase 3, multicenter study is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy and safety of lumateperone in this population. The study includes patients with moderate to severe depression diagnosed according to DSM-5 criteria, including those with psychotic features. Participants will be randomly assigned to receive either lumateperone 42 mg capsules or matching placebo capsules once daily for six weeks during the double-blind treatment period. The study consists of three distinct periods an initial screening lasting up to two weeks to determine eligibility, the six-week treatment phase with daily medication, and a one-week safety follow-up after the last dose to monitor any adverse effects. During the study, participants will undergo assessments including depression rating scales such as the Montgomery-Asberg Depression Rating Scale MADRS and Clinical Global Impression Scale-Severity. Safety evaluations will be conducted throughout, including a follow-up visit about one week after treatment ends. The total participation time may last up to nine weeks, encompassing screening, treatment, and safety monitoring.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of ABBV-932 when added to antidepressant therapies ADTs in adults with generalized anxiety disorder GAD who have not adequately responded to ADTs alone. The study is a Phase 2, randomized, double-blind, placebo-controlled trial involving approximately 315 adult participants across about 50 sites in the United States and Puerto Rico. ABBV-932 is an investigational oral drug developed as an adjunct treatment for GAD. Participants will be randomly assigned to one of three groups two different doses of ABBV-932 added to their prescribed ADTs, or a placebo added to their ADTs. The treatment period lasts for 6 weeks, during which participants will take oral capsules of ABBV-932 or placebo alongside their ongoing antidepressant treatment. Following the treatment, there is a 4-week follow-up period to monitor outcomes and safety. During the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate the treatments impact. The main outcomes measured include the number of adverse events and changes in anxiety levels assessed by the Hamilton Anxiety Scale. Additional assessments include worry questionnaires and depression rating scales. The total participation time is approximately 10 weeks, covering treatment and follow-up.
Actively Recruiting
Researchers are evaluating the efficacy of NBI-1065845 compared with a placebo as an additional treatment in adults with Major Depressive Disorder MDD. The study focuses on participants who have moderate to severe depression or persistent depressive disorder and who have not adequately responded to oral antidepressant treatments. This Phase 3, randomized, double-blind, placebo-controlled trial aims to assess how well NBI-1065845 improves symptoms of depression over the course of treatment. Participants will receive either NBI-1065845 tablets or matching placebo tablets, both administered orally once a day. The study treatment is given alongside participants ongoing oral antidepressant therapy, which they must continue at the same dose and frequency throughout the trial. The treatment period lasts for 56 days, during which participants are monitored closely. During the study, participants will undergo assessments including the Montgomery-sberg Depression Rating Scale MADRS to measure changes in depression symptoms, as well as evaluations using the Sheehan Disability Scale SDS and Clinical Global Impression-Severity Scale CGI-S at baseline and day 56. The trial includes safety monitoring and adherence to study procedures, with a total participation duration of at least 56 days.